Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28736460 | 0.80 | CES2 (0.33) | DAOCES2CES1SNCA | |
| SCHEMBL16467611 | 0.80 | DAO (0.54) | DAOERCC5FEN1 | |
| SCHEMBL1773654 | 0.74 | MAPK1 (0.38) | DAOCES2CES1NPC1LMNA | |
| SCHEMBL19439599 | 0.72 | DAO (0.48) | DAOERCC5FEN1 | |
| SCHEMBL16801819 | 0.70 | DAO (0.46) | DAOERCC5FEN1NPC1SNCA | |
| SCHEMBL1164060 | 0.70 | CES2 (0.38) | DAOCES2CES1MEN1LMNA | |
| SCHEMBL21720115 | 0.69 | ALDH1A1 (0.31) | — | |
| SCHEMBL27591651 | 0.69 | CES2 (0.37) | DAOCES2CES1KMT2ASNCA | |
| SCHEMBL23003653 | 0.68 | DAO (0.45) | DAOERCC5FEN1 | |
| SCHEMBL14997805 | 0.68 | DAO (0.45) | DAOERCC5FEN1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2025-06-05 | — | — | US | disclosed |
| CN-119698414-A | Indole-phenyl piperidine compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12240827-B2 | Serotonin 5-HT2B inhibitory compounds | ZOETIS SERVICES LLC (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240360067-A1 | DERIVATIVES OF ITACONIC ACID AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-10-31 | — | — | US | disclosed |
| CN-114989164-B | Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof | 詹森药业有限公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-3947360-B1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4384271-A1 | DERIVATIVES OF ITACONIC ACID AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Sitryx Therapeutics Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| US-20240124469-A1 | PIM KINASE INHIBITOR | HANGZHOU BIOSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| US-20240010606-A1 | FUMARATE DERIVATIVES AND THEIR MEDICAL USE | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-11 | — | — | US | disclosed |
| WO-2023246677-A1 | INDOLE-PHENYLPIPERIDINE COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2023-12-28 | — | — | WO | disclosed |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20110237588-A1 | Thienylpyri(mi)dinylazole | BAYER CROPSCIENCE AG (DE) | 2011-09-29 | — | — | US | disclosed |
| WO-2011101424-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| CN-102164908-A | Selective estrogen repector modulator for the treatment of osteoarthritis | LILLY CO ELI | 2011-08-24 | — | — | CN | disclosed |
| WO-2011076725-A1 | THIENYLPYRI (MI) DINYLAZOLE AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-06-30 | — | — | WO | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
| CN-101903364-A | Thiazoline urea and amide derivatives and methods of use thereof | ABBOTT LAB | 2010-12-01 | — | — | CN | disclosed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240827-B2 | Serotonin 5-HT2B inhibitory compounds | HTR2B, HTR1B, HTR5A | DAO 1044/4885ERCC5 3047/4885FEN1 4090/4885 |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | DAO 1279/4885ERCC5 4563/4885FEN1 3406/4885 |
| US-20250179046-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR5A | DAO 1044/4885ERCC5 3047/4885FEN1 4090/4885 |
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | DAO 938/4885ERCC5 3584/4885FEN1 2176/4885 |
| US-20240124469-A1 | PIM KINASE INHIBITOR | PIM1, PIM2, PIM3 | DAO 2489/4885ERCC5 4764/4885FEN1 4876/4885 |
| US-20240360067-A1 | DERIVATIVES OF ITACONIC ACID AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | NFKBIA, NFATC1, RORC | DAO 3191/4885ERCC5 1548/4885FEN1 3094/4885 |
| US-20240010606-A1 | FUMARATE DERIVATIVES AND THEIR MEDICAL USE | FH, SUCNR1, ARG2 | DAO 3781/4885ERCC5 1835/4885FEN1 2329/4885 |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | DAO 4126/4885ERCC5 3873/4885FEN1 2291/4885 |
| US-20110237588-A1 | Thienylpyri(mi)dinylazole | PADI1, TH, H1-3 | DAO 1481/4885ERCC5 4099/4885FEN1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.